Purinone derivative
AssigneeOno Pharmaceutical Co., Ltd.
InventorsShingo YAMAMOTO, Toshio YOSHIZAWA
Life of this patent
Estimating the term…
Abstract
Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
Claims4
1-17. (canceled)
9-(1-acryloyl-3-azetidinyl)-6-amino-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one or an optical isomer thereof or their mixture, a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof.
Dependencies are inferred from the claim text.